Expert Insights On An Evolving Treatment Landscape In Multiple Myeloma: Updates From EHA 2025 - Episode 15
EHA 2025 Insights: Emerging Developments and Future Perspectives for the Multiple Myeloma Treatment Landscape
Panelists discuss how emerging combination therapies such as bispecific antibodies with chimeric antigen receptor (CAR) T cells show promising response rates in patients with heavily refractory disease, while highlighting the ongoing unmet need to improve treatment access and educate community practices on advanced therapies.
Video content above is prompted by the following:
The European Hematology Association (EHA) 2025 Congress highlighted significant advances in bispecific antibody combinations, particularly the promising results from trials combining B-cell maturation antigen (BCMA)– and non–BCMA-targeted bispecific antibodies. The combination approach achieved approximately 80% response rates in heavily refractory patient populations with extramedullary disease, suggesting additive or potentially synergistic effects. However, increased infection rates accompany these combinations, requiring enhanced patient monitoring and education about infection prevention strategies, particularly in urban environments with higher pathogen exposure risks.
The expansion of CAR T-cell therapy options beyond current BCMA-targeted products represents another major development, with new cellular therapy platforms showing promise in early-phase trials. This diversification of CAR T approaches may address current limitations and expand treatment options for patients who do not respond to existing therapies. The field continues to grapple with optimizing dosing schedules for combination therapies, as few patients maintain original protocol dosing, suggesting initial regimens may be overly aggressive.
Critical unmet needs persist in multiple myeloma treatment accessibility and post-BCMA therapy strategies. With only 20% of eligible patients accessing CAR T therapy and limited data on post-BCMA treatment approaches, significant gaps remain in care delivery. Community practice education emerges as essential for democratizing advanced therapies, ensuring health care providers outside academic centers can safely administer and monitor novel treatments. The post-BCMA treatment landscape remains largely unexplored, representing a crucial area for future research as more patients exhaust BCMA-targeted options and require alternative therapeutic approaches.
Related Content:
